Denmark-based Novo Nordisk (CPH: NOVO-B) has announced a significant agreement to acquire Germany’s Cardior, a leading expert in RNA biology focused on the prevention, repair, and reversal of cardiovascular diseases (CVDs). The deal, valued at EUR 1.025 billion, which includes upfront and milestone payments, is anticipated to finalize in the second quarter of 2024, pending customary conditions.
Cardior’s lead compound, CDR132L, is a Phase II candidate targeting heart failure with reduced ejection fraction (HFrEF) following myocardial infarction. This innovative drug, poised to be a first-in-class treatment, aims to inhibit the microRNA molecule miR-132, thereby halting and partially reversing the cellular pathology associated with heart failure.
In addition to the acquisition, Novo Nordisk plans to initiate a mid-stage trial for CDR132L focused on cardiac hypertrophy, further expanding its commitment to advancing cardiovascular therapeutics.- Flcube.com
